Literature DB >> 23588372

STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target.

Emanuele S G d'Amore1, Carlo Visco, Andrea Menin, Barbara Famengo, Paolo Bonvini, Elena Lazzari.   

Abstract

ALK-positive large B-cell lymphomas usually harbor clathrin (CLTC)-ALK rearrangement or, more rarely, nucleophosmin (NPM)-ALK fusion gene. Here we report a large B-cell lymphoma with a peculiar pattern of diffuse and cytoplasmic immunohistochemical staining and carrying sequestosome 1 (SQSTM1)-ALK rearrangement, identified by reverse transcription polymerase chain reaction analysis and Rapid Amplification of cDNA Ends analysis and confirmed by fluorescence in situ hybridization with specific dual-color fusion probes. The gene fusion product and the transcription factor STAT3 are both phosphorylated, and thereby the pathogenetic mechanism of this case shows important analogies with that of NPM-ALK and CLTC-ALK lymphomas, in which STAT3 plays a central role in the lymphomagenesis. Consequently, STAT3 inhibition provides a possible therapeutic target also for lymphomas with SQSTM1-ALK variant translocation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588372     DOI: 10.1097/PAS.0b013e318287791f

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

Review 1.  ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.

Authors:  Kana Sakamoto; Hideki Nakasone; Yuki Togashi; Seiji Sakata; Naoko Tsuyama; Satoko Baba; Akito Dobashi; Reimi Asaka; Chien-Chen Tsai; Shih-Sung Chuang; Koji Izutsu; Yoshinobu Kanda; Kengo Takeuchi
Journal:  Int J Hematol       Date:  2016-01-18       Impact factor: 2.490

2.  ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.

Authors:  Leona A Doyle; Adrián Mariño-Enriquez; Christopher D M Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2015-04-10       Impact factor: 7.842

3.  Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.

Authors:  Kazunori Honda; Shigenori Kadowaki; Kyoko Kato; Nobuhiro Hanai; Yasuhisa Hasegawa; Yasushi Yatabe; Kei Muro
Journal:  Invest New Drugs       Date:  2019-02-21       Impact factor: 3.850

Review 4.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

5.  Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature.

Authors:  Jian Li; Jian Ouyang; Rongfu Zhou; Bing Chen; Yong Xu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 6.  CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.

Authors:  Jing Li; Shu Zhao; Jingxuan Wang; Jingyu Chen; Wen Wen; Qingyuan Zhang
Journal:  Tumour Biol       Date:  2015-10-12

7.  A novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocation.

Authors:  Y Nakamura; Y Ito; N Wakimoto; E Kakegawa; Y Uchida; M Bessho
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

Review 8.  ALK: a tyrosine kinase target for cancer therapy.

Authors:  Vijaykumar R Holla; Yasir Y Elamin; Ann Marie Bailey; Amber M Johnson; Beate C Litzenburger; Yekaterina B Khotskaya; Nora S Sanchez; Jia Zeng; Md Abu Shufean; Kenna R Shaw; John Mendelsohn; Gordon B Mills; Funda Meric-Bernstam; George R Simon
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-01

Review 9.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature.

Authors:  Xiang-Nan Jiang; Bao-Hua Yu; Wei-Ge Wang; Xiao-Yan Zhou; Xiao-Qiu Li
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

Review 10.  Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Authors:  Geeta Geeta Sharma; Ines Mota; Luca Mologni; Enrico Patrucco; Carlo Gambacorti-Passerini; Roberto Chiarle
Journal:  Cancers (Basel)       Date:  2018-02-28       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.